{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:12:50Z","timestamp":1790874770049,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Psychosomatic Research"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.jpsychores.2007.05.013","type":"journal-article","created":{"date-parts":[[2007,7,27]],"date-time":"2007-07-27T10:29:56Z","timestamp":1185532196000},"page":"131-135","source":"Crossref","is-referenced-by-count":84,"title":["Depression following pegylated interferon-alpha: Characteristics and vulnerability"],"prefix":"10.1016","volume":"63","author":[{"given":"Francis E.","family":"Lotrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Rabinovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gironda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychores.2007.05.013_bib1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7326\/0003-4819-140-6-200403160-00014","article-title":"Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force","volume":"140","author":"Chou","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib2","first-page":"921","article-title":"Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma","volume":"25","author":"Donnelly","year":"1998","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000026485","article-title":"Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha","volume":"37","author":"Malaguarnera","year":"1998","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib4","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1200\/JCO.2000.18.11.2316","article-title":"Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions","volume":"18","author":"Trask","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib5","first-page":"157","article-title":"Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population","volume":"96","author":"Ho","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00001504-200011000-00034","article-title":"Psychological and behavioural effects of interferons","volume":"13","author":"Bonaccorso","year":"2000","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","article-title":"Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review","volume":"157","author":"Dieperink","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioral effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/00001504-199911000-00019","article-title":"Psychological stress, cytokines, and the inflammatory response system","volume":"12","author":"Maes","year":"1999","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/brbi.2001.0647","article-title":"T-Helper-1 and T-helper-2 responses in psychiatric disorders","volume":"15","author":"Schwarz","year":"2001","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1017\/S0033291701003841","article-title":"Acute sickness behavior: an immune system-to-brain communication?","volume":"31","author":"Vollmer-Conna","year":"2001","journal-title":"Psychol Med"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib12","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0889-1591(02)00078-8","article-title":"Cytokines and depression: the need for a new paradigm","volume":"17","author":"Capuron","year":"2003","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/brbi.2000.0613","article-title":"Cytokine-induced sickness behavior: where do we stand?","volume":"15","author":"Dantzer","year":"2001","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/sj.mp.4000572","article-title":"Cytokines and depression: fortuitous or causative association?","volume":"4","author":"Dantzer","year":"1999","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0166-2236(00)02088-9","article-title":"Cytokine-induced sickness behaviour: mechanisms and implications","volume":"25","author":"Konsman","year":"2002","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-0-585-37970-8_14","article-title":"Stress, depression, and the role of cytokines","volume":"461","author":"Leonard","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0278-5846(94)00101-M","article-title":"Evidence for an immune response in major depression: a review and hypothesis","volume":"19","author":"Maes","year":"1995","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.psy.41.5.439","article-title":"Prophylactic treatment of depression induced by interferon-a","volume":"41","author":"Hauser","year":"2000","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3928\/0048-5713-20030601-08","article-title":"Comanagement of depression and HCV treatment","volume":"33","author":"Loftis","year":"2003","journal-title":"Psychiatr Ann"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3928\/0048-5713-20030601-04","article-title":"Psychiatric issues in patients with hepatitis C","volume":"33","author":"Goldsmith","year":"2003","journal-title":"Psychiatr Ann"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib22","first-page":"292A","article-title":"Co-morbid behavioral emotional disturbances (BED) associated with hepatitis C virus (HCV): prevalence, compliance and treatment responses using a multidiscipline approach","volume":"36","author":"Goldsmith","year":"2002","journal-title":"Hepatology (abstract)"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon-a: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1176\/appi.psy.47.2.93","article-title":"Hepatitis C treatment for people with severe mental illness","volume":"47","author":"Mistler","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjo.82.3.323","article-title":"Interferon associated retinopathy","volume":"82","author":"Hayasaka","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0002-9394(01)00836-4","article-title":"Retinopathy associated with high-dose interferon alfa-2b therapy","volume":"131","author":"Hejny","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s002130000549","article-title":"Prefrontal cortical hypometabolism during low-dose interferon alpha treatment","volume":"152","author":"Juengling","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1176\/jnp.8.1.74","article-title":"Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals","volume":"8","author":"Mapou","year":"1996","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jama.252.7.938","article-title":"Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer","volume":"252","author":"Adams","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/107999001300177457","article-title":"Neuropsychiatric effects and type of IFN-a in chronic hepatitis C","volume":"21","author":"Malaguarnera","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004714-200202000-00014","article-title":"Increased depressive ratings in patients with hepatitis C receiving interferon-[alpha]-based immunotherapy are related to interferon-[alpha]-induced changes in the serotonergic system","volume":"22","author":"Bonaccorso","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib32","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1023\/A:1018852309885","article-title":"Effect of interferon-a treatment of chronic hepatitis C on health-related quality of life","volume":"42","author":"Hunt","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(98)04793-X","article-title":"Treatment with interferon-a in patients with chronic hepatitis and mood or anxiety disorders","volume":"354","author":"Pariante","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib34","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archinte.147.9.1577","article-title":"Psychiatric complications of long-term interferon alfa therapy","volume":"147","author":"Renault","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.psy.44.2.104","article-title":"A prospective study of neuropsychiatric symptoms associated with interferon-a-2b and ribavirin therapy for patients with chronic hepatitis C","volume":"44","author":"Dieperink","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4088\/JCP.v64n0614","article-title":"Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy","volume":"64","author":"Kraus","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib37","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1097\/00002030-200210180-00016","article-title":"Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients","volume":"16","author":"Rockstroh","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib38","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon afla-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/(SICI)1097-0142(19980801)83:3<482::AID-CNCR17>3.0.CO;2-S","article-title":"Neurotoxicity of interferon-a in melanoma therapy: results from a randomized controlled trial","volume":"83","author":"Caraceni","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib40","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1212\/WNL.45.5.947","article-title":"Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia","volume":"45","author":"Pavol","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2893.2000.00215.x","article-title":"Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C","volume":"7","author":"Cotler","year":"2000","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000067682","article-title":"Assessment of depression in patients with chronic hepatitis: effect of interferon treatment","volume":"20","author":"Koskinas","year":"2002","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/15622970310029904","article-title":"Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients","volume":"4","author":"Gohier","year":"2003","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0165-0327(02)00264-1","article-title":"Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus","volume":"72","author":"Bonaccorso","year":"2002","journal-title":"J Affect Dis"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib45","first-page":"42","article-title":"Use of peg-intron in combined treatment of chronic liver disease caused by HIV infection","volume":"1","author":"Pomova","year":"2003","journal-title":"Eksp Klin Gastroenterol"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0163-8343(02)00239-6","article-title":"Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study","volume":"25","author":"Horikawa","year":"2003","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib47","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.mp.4001119","article-title":"A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C","volume":"7","author":"Hauser","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib48","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1056\/NEJM199904293401716","article-title":"Prediction of the depressive effects of interferon alfa therapy by the patients initial affective state","volume":"340","author":"Capuron","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/00048679609076076","article-title":"An overview of depression-prone personality traits and the role of interpersonal sensitivity","volume":"30","author":"Boyce","year":"1996","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib50","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/(SICI)1520-6394(1998)7:4<188::AID-DA7>3.0.CO;2-6","article-title":"Hepatitis C and depression","volume":"7","author":"Yates","year":"1998","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib51","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3928\/0048-5713-20030601-05","article-title":"Psychiatric and substance use disorder comorbidity with hepatitis C","volume":"33","author":"Straits-Troster","year":"2003","journal-title":"Psychiatr Ann"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0022-3999(00)00155-0","article-title":"Depression, fatigue, and functional disability in patients with chronic hepatitis C","volume":"49","author":"Dwight","year":"2000","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0165-0327(00)00186-5","article-title":"Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2","volume":"63","author":"Patten","year":"2001","journal-title":"J Affect Dis"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0924-9338(03)00052-X","article-title":"Depression and anxiety in coronary artery bypass grafting patients","volume":"18","author":"Rymaszewska","year":"2003","journal-title":"European Psychiatry"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib55","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0895-4356(96)00017-0","article-title":"The incidence of depression in new users of beta-blockers and selected antihypertensives","volume":"49","author":"Gerstman","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jpsychores.2007.05.013_bib56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJM200108023450514","article-title":"Paroxetine for the prevention of depression induced by interferon alfa","volume":"345","author":"Miller","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Journal of Psychosomatic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399907002164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399907002164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T10:43:54Z","timestamp":1556707434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022399907002164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0022399907002164"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychores.2007.05.013","relation":{},"ISSN":["0022-3999"],"issn-type":[{"value":"0022-3999","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}